---
schema_version: "secwatch.filing_event.v1"
accession: "0001438133-26-000148"
form_type: "8-K"
ticker: "TNDM"
cik: "0001438133"
company_name: "TANDEM DIABETES CARE INC"
filed_at: "2026-11-13T13:35:29+00:00"
generated_at: "2026-11-13T13:40:24.265064+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tandem wins FDA 510(k) clearance for tubeless Tandem Mobi insulin pump; US launch planned for H1 2027

## Summary
- FDA granted 510(k) clearance on November 12, 2026 for Tandem Mobi as a tubeless automated insulin delivery system.
- New tubeless cartridge and infusion set converts the existing Tandem Mobi pump; infusion set cleared for up to 7 days of wear, cartridge for 3 days of use.
- Mobi keeps Control-IQ+ hybrid closed-loop technology and is now cleared for both tubeless and tubed infusion, which Tandem calls the only pump offering both options.
- Full US commercial launch of the tubeless cartridge and infusion set is planned for the first half of 2027.

## SEC filing metadata
- accession: 0001438133-26-000148
- form_type: 8-K
- ticker: TNDM
- cik: 0001438133
- company_name: TANDEM DIABETES CARE INC
- filed_at: 2026-11-13T13:35:29+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438133/000143813326000148/0001438133-26-000148-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438133/000143813326000148/tndm-20261112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438133-26-000148
- JSON: https://secwatch.observer/filing/0001438133-26-000148.json
- Plain text: https://secwatch.observer/filing/0001438133-26-000148.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.
